RESUMO

This study assessed the effects of dexamethasone treatment on farrowing performance and piglet traits in the first 5 days of life in multiparous sows, a high-risk group for stillbirths and prolonged farrowing. In this study, 185 multiparous sows (parity 4.25 ± 0.14) were selected on the day of farrowing and divided into three treatments: CON - control, without dexamethasone treatment; DexaPF - treatment with dexamethasone (20 mg im per female) at the time of copious colostrum secretion (pre-farrowing); and DexaFO - treatment with dexamethasone (20 mg im per female) when the first piglet was born (farrowing onset). All sows and their litters were monitored for farrowing duration, obstetric interventions, colostrum yield and intake, newborn piglet traits, and piglet performance until 5 d of age. A subsample of 106 females (∼35 per treatment) had their blood glucose concentration checked hourly shortly after the first piglet was born until the end of farrowing. Additionally, blood samples from 42 litters were collected for immunocrit evaluation. The results showed no differences regarding farrowing duration (CON = 258.02 ± 13.81 min; DexaPF = 251.29 ± 13.60 min; DexaFO = 294.92 ± 13.89 min; P = 0.06) and obstetric intervention rates among treatments (CON = 36.58 ± 6.78 %; DexaPF = 42.16 ± 6.89 %; DexaFO = 48.05 ± 7.08 %; P = 0.45). The blood glucose concentration during farrowing was higher in DexaPF (94.56 ± 1.57 mg/dL; P < 0.001) than in CON (73.50 ± 1.72 mg/dL) and DexaFO (87.94 ± 1.80 mg/dL). No differences were observed regarding total piglets born and born alive, stillborn, newborn piglet vitality, colostrum intake, immunocrit, colostrum yield, and glycemia and rectal temperature at 24 h of age (P ≥ 0.13). Regarding meconium staining, higher percentages of piglets born without meconium staining were observed in DexaFO (54.77 ± 5.21 %; P = 0.02) compared with CON (48.58 ± 5.26 %), and no difference was observed for the DexaPF group (53.23 ± 5.21 %). In addition, a higher unbroken umbilical cord rate was observed in DexaFO (92.41 ± 1.31 %; P < 0.01) than the CON or DexaPF (86.91 ± 1.97 % and 89.31 ± 1.67 %, respectively). However, the treatments did not affect piglet performance (weight gain and survival) until 5 d of age (P ≥ 0.15). In summary, dexamethasone treatment in periparturient multiparous sows did not improve farrowing performance and key production parameters, such as the piglet weight gain and survival up to 5 d of age.

Assuntos

RESUMO

This study evaluated the relationship between the steroidal anti-inflammatory action of dexamethasone treatment in primiparous sows and farrowing and piglet performance in the first 5 d of life. For this purpose, 234 gilts were selected on the day of farrowing and distributed among three treatments: CON - control, without dexamethasone treatment; DexaPF - treatment with dexamethasone (20 mg im) per female at the moment of copious colostrum secretion (pre-farrowing); and DexaFO - treatment with dexamethasone (20 mg im), per female when the first piglet was born (farrowing onset). All females and their litters were evaluated regarding farrowing duration, obstetric interventions, colostrum yield and intake, newborn piglet traits, and piglet performance until 5 d of age. A subsample of 79 females (∼26 per treatment) had their blood glucose concentration evaluated hourly shortly after the first piglet was born until the end of farrowing. Additionally, blood samples from 11 litters per treatment were collected for immunocrit evaluation. As a result, faster farrowing was observed in the DexaPF treatment (188.14 min; P = 0.002) compared with CON (229.99 min) and DexaFO (221.79 min). Additionally, lower obstetric intervention rates were observed in sows treated with dexamethasone (DexaPF = 7.69%; DexaFO = 5.13%) compared with CON (19.23%; P = 0.02). The sow's blood glucose concentration during farrowing was higher in DexaPF (90.55 mg/dL) than in CON (73.15 mg/dL) and DexaFO (80.06 mg/dL) treatments (P < 0.01). Besides the effect on farrowing duration, no differences among treatments were observed regarding piglets born alive and stillbirths, newborn piglet vitality, colostrum consumption, immunocrit, and colostrum yield (P ≥ 0.17). Regarding piglet traits, higher percentages of piglets born without meconium staining and lower percentages of piglets with meconium scores 2 and 3 were observed in the groups treated with dexamethasone (DexaPF and DexaFO; P < 0.01) compared with CON. However, piglet weight gain and survival rate until 5 d of age were not affected by the treatment (P ≥ 0.61). In summary, dexamethasone treatment before farrowing onset, in primiparous sows, had the potential to reduce the farrowing duration and the necessity of obstetric intervention, but it did not affect the main productive parameters such as the occurrence of stillbirths, piglet weight gain, and survival rates until 5 d of age.

Assuntos

RESUMO

Callithrix jacchus is a small primate characteristic to the Brazilian Northeast. We considered relevant to report details on the anesthetic protocol and the surgical technique of cesarean sections applied in three cases of dystocia in C. jacchus. Animals were subjected to cesarean intervention because their small body size did not allow for less invasive obstetric maneuvers. The anesthetic protocol was shown to be efficient, safe and original in its equipment adaptations, by means of endotracheal intubation with a 14G catheter. The surgical procedure was relatively simple and did not offer a major challenge in the exposure of the uterus. The suture of the uterus, abdominal wall and skin did not present technical difficulties, however even the thinnest sutures used in dogs and cats may be considered too thick considering the marmosets' small body size.

Callithrix jacchus é um pequeno primata característico do Nordeste brasileiro. Considerou-se importante a descrição do protocolo anestésico e da técnica cirúrgica da cesariana aplicada em três casos de distocia em C. jacchus. Os animais foram submetidos à intervenção cesariana, devido o pequeno tamanho dos seus corpos, o qual não permite manobras obstétricas menos invasivas. O protocolo anestésico mostrou-se eficiente, seguro e original em suas adaptações anestésicas por meio de intubação endotraqueal com um cateter 14G. O procedimento cirúrgico foi relativamente simples e a exposição do útero não foi um grande desafio. Não houveram grandes dificuldades quanto a técnica de sutura do útero, da parede abdominal e da pele, porém os mais finos fios de suturas utilizados em cães e gatos são muito grossos considerando o tamanho do pequeno corpo dos saguis.

Callithrix jacchus es un pequeño primata característico del Nordeste Brasileño. Se considera importante la descripción de un protocolo anestésico y de una técnica quirúrgica de la cesaría aplicada en tres casos de distocia en C. jacchus. Los animales fueron sometidos a una intervención por cesárea, debido al pequeño tamaño de sus cuerpos, lo cual, no permitía maniobras obstétricas menos invasivas. El protocolo anestésico se mostro eficiente, seguros y originales en sus adaptaciones anestésicas por medio de la intubación endotraqueal con un catéter 14G. El procedimiento quirúrgico fue relativamente sencillo y la exposición del útero no fue de gran desafío. No presentó dificultades en cuanto la técnica de sutura al útero, pared abdominal y piel, sin embargo, incluso las más finas suturas utilizadas en perros y gatos es muy gruesa considerando el tamaño del pequeño cuerpo de los titíes.

Assuntos

RESUMO

Callithrix jacchus is a small primate characteristic to the Brazilian Northeast. We considered relevant to report details on the anesthetic protocol and the surgical technique of cesarean sections applied in three cases of dystocia in C. jacchus. Animals were subjected to cesarean intervention because their small body size did not allow for less invasive obstetric maneuvers. The anesthetic protocol was shown to be efficient, safe and original in its equipment adaptations, by means of orotracheal intubation with a 14G catheter. The surgical procedure was relatively simple and did not offer a major challenge in the exposure of the uterus. The suture of the uterus, abdominal wall and skin did not present technical difficulties, however even the thinnest sutures used in dogs and cats may be considered too thick considering the marmosets small body size.

RESUMO

O presente estudo teve como objetivo avaliar o efeito da aplicação de um análogo sintético da PGF2 (cloprostenol sodico), associado à ocitocina ou carbetocina, sobre a eficiência da indução ao parto em suínos. O experimento I foi realizado com 284 fêmeas, distribuídas em quatro tratamentos: cloprostenol; cloprostenol e 0,100mg de carbetocina; cloprostenol e 10UI de ocitocina; solução salina (NaCl 0,9 por cento). No experimento II, foram utilizadas 276 fêmeas, distribuídas em quatro tratamentos: cloprostenol; cloprostenol e 0,10mg de carbetocina; cloprostenol e 0,05mg de carbetocina; cloprostenol e 10UI de ocitocina. A indução do parto foi realizada aos 113 dias de gestação, pela aplicação de 0,175mg de cloprostenol, via submucosa vulvar. A carbetocina ou a ocitocina foram aplicadas 24h após a aplicação de cloprostenol, pela via intramuscular. O intervalo indução-parto foi menor (P<0,05) nos grupos cujo parto foi induzido com cloprostenol, em comparação ao grupo sem indução do parto. A aplicação de carbetocina ou ocitocina resultou em maior concentração dos partos (P<0,05) até 26 e 28h após a administração de cloprostenol. A utilização de carbetocina resultou em menor (P<0,05) duração do parto. No experimento I, o uso de ocitocina ou de carbetocina resultou em maior natimortalidade (P<0,05) do que no grupo sem indução do parto. Além disso, a natimortalidade foi maior (P<0,05) com o uso de carbetocina do que na indução somente com cloprostenol. No experimento II, não houve diferença na natimortalidade (P>0,05) entre os tratamentos. A utilização de ocitócitos, em associação com cloprostenol, resulta em partos antecipados e mais sincronizados. O uso associado de cloprostenol e carbetocina reduz o tempo de parto e 99 por cento ou mais dos partos ocorrem em até quatro horas após a aplicação de carbetocina, independentemente da dose utilizada.

The aim of the present study was to evaluate the effect of a synthetic analogue of PGF2 (sodium cloprostenol) associated to carbetocin or oxytocin on the efficiency of farrowing induction in swine. In Experiment I, 284 females were distributed in four treatments: - cloprostenol; - cloprostenol and 0.10mg of carbetocin; - cloprostenol and 10UI of oxytocin; and saline solution. In Experiment II, 276 females were distributed in four treatments: cloprostenol; cloprostenol and 0.10mg of carbetocin; cloprostenol and 0.05mg of carbetocin; and cloprostenol and 10UI of oxytocin. Farrowing induction was performed at 113 days of gestation using an injection of 0.175mg cloprostenol by vulvar submucosal route. Carbetocin or oxytocin was administered 24h after cloprostenol, by intramuscular route. The interval induction-farrowing was shorter (P<0.05) in groups with cloprostenol compared to the group without farrowing induction. Cumulative farrowing, within 26h and 28h after cloprostenol administration, was higher (P<0.05) when carbetocin or oxytocin was used. The use of carbetocin resulted in a shorter (P<0.05) farrowing length. In experiment I, higher stillbirth rate (P<0.05) was observed with the use of carbetocin or oxytocin compared to group without farrowing induction. Furthermore, stillbirth rate was higher (P<0.05) with cloprostenol + carbetocin than with cloprostenol alone. In experiment II, there was no difference (P>0.05) in stillbirth rate among treatments. The use of oxytocic drugs, in association with cloprostenol, results in anticipated and more synchronized farrowings. Following the use of carbetocin in association with cloprostenol, occurs a reduction in farrowing length and 99 percent or more of farrowings take place within 4h after carbetocin administration, regardless of the dose used.

RESUMO

The aim of the present study was to evaluate the effect of a synthetic analogue of PGF2 (sodium cloprostenol) associated to carbetocin or oxytocin on the efficiency of farrowing induction in swine. In Experiment I, 284 females were distributed in four treatments: - cloprostenol; - cloprostenol and 0.10mg of carbetocin; - cloprostenol and 10UI of oxytocin; and saline solution. In Experiment II, 276 females were distributed in four treatments: cloprostenol; cloprostenol and 0.10mg of carbetocin; cloprostenol and 0.05mg of carbetocin; and cloprostenol and 10UI of oxytocin. Farrowing induction was performed at 113 days of gestation using an injection of 0.175mg cloprostenol by vulvar submucosal route. Carbetocin or oxytocin was administered 24h after cloprostenol, by intramuscular route. The interval induction-farrowing was shorter (P 0.05) in groups with cloprostenol compared to the group without farrowing induction. Cumulative farrowing, within 26h and 28h after cloprostenol administration, was higher (P 0.05) when carbetocin or oxytocin was used. The use of carbetocin resulted in a shorter (P 0.05) farrowing length. In experiment I, higher stillbirth rate (P 0.05) was observed with the use of carbetocin or oxytocin compared to group without farrowing induction. Furthermore, stillbirth rate was higher (P 0.05) with cloprostenol + carbetocin than with cloprostenol alone. In experiment II, there was no difference (P>0.05) in stillbirth rate among treatments. The use of oxytocic drugs, in association with cloprostenol, results in anticipated and more synchronized farrowings. Following the use of carbetocin in association with cloprostenol, occurs a reduction in farrowing length and 99% or more of farrowings take place within 4h after carbetocin administration, regardless of the dose used.

O presente estudo teve como objetivo avaliar o efeito da aplicação de um análogo sintético da PGF2 (cloprostenol sodico), associado à ocitocina ou carbetocina, sobre a eficiência da indução ao parto em suínos. O experimento I foi realizado com 284 fêmeas, distribuídas em quatro tratamentos: cloprostenol; cloprostenol e 0,100mg de carbetocina; cloprostenol e 10UI de ocitocina; solução salina (NaCl 0,9%). No experimento II, foram utilizadas 276 fêmeas, distribuídas em quatro tratamentos: cloprostenol; cloprostenol e 0,10mg de carbetocina; cloprostenol e 0,05mg de carbetocina; cloprostenol e 10UI de ocitocina. A indução do parto foi realizada aos 113 dias de gestação, pela aplicação de 0,175mg de cloprostenol, via submucosa vulvar. A carbetocina ou a ocitocina foram aplicadas 24h após a aplicação de cloprostenol, pela via intramuscular. O intervalo indução-parto foi menor (P 0,05) nos grupos cujo parto foi induzido com cloprostenol, em comparação ao grupo sem indução do parto. A aplicação de carbetocina ou ocitocina resultou em maior concentração dos partos (P 0,05) até 26 e 28h após a administração de cloprostenol. A utilização de carbetocina resultou em menor (P 0,05) duração do parto. No experimento I, o uso de ocitocina ou de carbetocina resultou em maior natimortalidade (P 0,05) do que no grupo sem indução do parto. Além disso, a natimortalidade foi maior (P 0,05) com o uso de carbetocina do que na indução somente com cloprostenol. No experimento II, não houve diferença na natimortalidade (P>0,05) entre os tratamentos. A utilização de ocitócitos, em associação com cloprostenol, resulta em partos antecipados e mais sincronizados. O uso associado de cloprostenol e carbetocina reduz o tempo de parto e 99% ou mais dos partos ocorrem em até quatro horas após a aplicação de carbetocina, independentemente da dose utilizada.

RESUMO

The aim of the present study was to evaluate the effect of a synthetic analogue of PGF2 (sodium cloprostenol) associated to carbetocin or oxytocin on the efficiency of farrowing induction in swine. In Experiment I, 284 females were distributed in four treatments: - cloprostenol; - cloprostenol and 0.10mg of carbetocin; - cloprostenol and 10UI of oxytocin; and saline solution. In Experiment II, 276 females were distributed in four treatments: cloprostenol; cloprostenol and 0.10mg of carbetocin; cloprostenol and 0.05mg of carbetocin; and cloprostenol and 10UI of oxytocin. Farrowing induction was performed at 113 days of gestation using an injection of 0.175mg cloprostenol by vulvar submucosal route. Carbetocin or oxytocin was administered 24h after cloprostenol, by intramuscular route. The interval induction-farrowing was shorter (P 0.05) in groups with cloprostenol compared to the group without farrowing induction. Cumulative farrowing, within 26h and 28h after cloprostenol administration, was higher (P 0.05) when carbetocin or oxytocin was used. The use of carbetocin resulted in a shorter (P 0.05) farrowing length. In experiment I, higher stillbirth rate (P 0.05) was observed with the use of carbetocin or oxytocin compared to group without farrowing induction. Furthermore, stillbirth rate was higher (P 0.05) with cloprostenol + carbetocin than with cloprostenol alone. In experiment II, there was no difference (P>0.05) in stillbirth rate among treatments. The use of oxytocic drugs, in association with cloprostenol, results in anticipated and more synchronized farrowings. Following the use of carbetocin in association with cloprostenol, occurs a reduction in farrowing length and 99% or more of farrowings take place within 4h after carbetocin administration, regardless of the dose used.

O presente estudo teve como objetivo avaliar o efeito da aplicação de um análogo sintético da PGF2 (cloprostenol sodico), associado à ocitocina ou carbetocina, sobre a eficiência da indução ao parto em suínos. O experimento I foi realizado com 284 fêmeas, distribuídas em quatro tratamentos: cloprostenol; cloprostenol e 0,100mg de carbetocina; cloprostenol e 10UI de ocitocina; solução salina (NaCl 0,9%). No experimento II, foram utilizadas 276 fêmeas, distribuídas em quatro tratamentos: cloprostenol; cloprostenol e 0,10mg de carbetocina; cloprostenol e 0,05mg de carbetocina; cloprostenol e 10UI de ocitocina. A indução do parto foi realizada aos 113 dias de gestação, pela aplicação de 0,175mg de cloprostenol, via submucosa vulvar. A carbetocina ou a ocitocina foram aplicadas 24h após a aplicação de cloprostenol, pela via intramuscular. O intervalo indução-parto foi menor (P 0,05) nos grupos cujo parto foi induzido com cloprostenol, em comparação ao grupo sem indução do parto. A aplicação de carbetocina ou ocitocina resultou em maior concentração dos partos (P 0,05) até 26 e 28h após a administração de cloprostenol. A utilização de carbetocina resultou em menor (P 0,05) duração do parto. No experimento I, o uso de ocitocina ou de carbetocina resultou em maior natimortalidade (P 0,05) do que no grupo sem indução do parto. Além disso, a natimortalidade foi maior (P 0,05) com o uso de carbetocina do que na indução somente com cloprostenol. No experimento II, não houve diferença na natimortalidade (P>0,05) entre os tratamentos. A utilização de ocitócitos, em associação com cloprostenol, resulta em partos antecipados e mais sincronizados. O uso associado de cloprostenol e carbetocina reduz o tempo de parto e 99% ou mais dos partos ocorrem em até quatro horas após a aplicação de carbetocina, independentemente da dose utilizada.

RESUMO

The aim of the present study was to evaluate the effect of a synthetic analogue of PGF2 (sodium cloprostenol) associated to carbetocin or oxytocin on the efficiency of farrowing induction in swine. In Experiment I, 284 females were distributed in four treatments: - cloprostenol; - cloprostenol and 0.10mg of carbetocin; - cloprostenol and 10UI of oxytocin; and saline solution. In Experiment II, 276 females were distributed in four treatments: cloprostenol; cloprostenol and 0.10mg of carbetocin; cloprostenol and 0.05mg of carbetocin; and cloprostenol and 10UI of oxytocin. Farrowing induction was performed at 113 days of gestation using an injection of 0.175mg cloprostenol by vulvar submucosal route. Carbetocin or oxytocin was administered 24h after cloprostenol, by intramuscular route. The interval induction-farrowing was shorter (P 0.05) in groups with cloprostenol compared to the group without farrowing induction. Cumulative farrowing, within 26h and 28h after cloprostenol administration, was higher (P 0.05) when carbetocin or oxytocin was used. The use of carbetocin resulted in a shorter (P 0.05) farrowing length. In experiment I, higher stillbirth rate (P 0.05) was observed with the use of carbetocin or oxytocin compared to group without farrowing induction. Furthermore, stillbirth rate was higher (P 0.05) with cloprostenol + carbetocin than with cloprostenol alone. In experiment II, there was no difference (P>0.05) in stillbirth rate among treatments. The use of oxytocic drugs, in association with cloprostenol, results in anticipated and more synchronized farrowings. Following the use of carbetocin in association with cloprostenol, occurs a reduction in farrowing length and 99% or more of farrowings take place within 4h after carbetocin administration, regardless of the dose used.

O presente estudo teve como objetivo avaliar o efeito da aplicação de um análogo sintético da PGF2 (cloprostenol sodico), associado à ocitocina ou carbetocina, sobre a eficiência da indução ao parto em suínos. O experimento I foi realizado com 284 fêmeas, distribuídas em quatro tratamentos: cloprostenol; cloprostenol e 0,100mg de carbetocina; cloprostenol e 10UI de ocitocina; solução salina (NaCl 0,9%). No experimento II, foram utilizadas 276 fêmeas, distribuídas em quatro tratamentos: cloprostenol; cloprostenol e 0,10mg de carbetocina; cloprostenol e 0,05mg de carbetocina; cloprostenol e 10UI de ocitocina. A indução do parto foi realizada aos 113 dias de gestação, pela aplicação de 0,175mg de cloprostenol, via submucosa vulvar. A carbetocina ou a ocitocina foram aplicadas 24h após a aplicação de cloprostenol, pela via intramuscular. O intervalo indução-parto foi menor (P 0,05) nos grupos cujo parto foi induzido com cloprostenol, em comparação ao grupo sem indução do parto. A aplicação de carbetocina ou ocitocina resultou em maior concentração dos partos (P 0,05) até 26 e 28h após a administração de cloprostenol. A utilização de carbetocina resultou em menor (P 0,05) duração do parto. No experimento I, o uso de ocitocina ou de carbetocina resultou em maior natimortalidade (P 0,05) do que no grupo sem indução do parto. Além disso, a natimortalidade foi maior (P 0,05) com o uso de carbetocina do que na indução somente com cloprostenol. No experimento II, não houve diferença na natimortalidade (P>0,05) entre os tratamentos. A utilização de ocitócitos, em associação com cloprostenol, resulta em partos antecipados e mais sincronizados. O uso associado de cloprostenol e carbetocina reduz o tempo de parto e 99% ou mais dos partos ocorrem em até quatro horas após a aplicação de carbetocina, independentemente da dose utilizada.